Notice2024-15371
Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of New Drug Application for EXKIVITY (Mobocertinib Succinate) Capsule, Equivalent to 40 Milligrams Base
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 15, 2024
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for EXKIVITY (mobocertinib succinate) capsule, equivalent to (EQ) 40 milligrams (mg) base, held by Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave., Lexington, MA 02421 (Takeda). Takeda has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 135 (Monday, July 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 135 (Monday, July 15, 2024)]
[Notices]
[Pages 57418-57419]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-15371]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-3165]
Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of
New Drug Application for EXKIVITY (Mobocertinib Succinate) Capsule,
Equivalent to 40 Milligrams Base
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of the new drug application (NDA) for EXKIVITY
(mobocertinib succinate) capsule, equivalent to (EQ) 40 milligrams (mg)
base, held by Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave.,
Lexington, MA 02421 (Takeda). Takeda has voluntarily requested that FDA
withdraw approval of this application and has waived its opportunity
for a hearing.
DATES: Approval is withdrawn as of July 15, 2024.
FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-
796-3137, <a href="/cdn-cgi/l/email-protection#fcb795919e998e9085d2b099948e9a999098bc9a989dd294948fd29b938a"><span class="__cf_email__" data-cfemail="db90b2b6b9bea9b7a2f597beb3a9bdbeb7bf9bbdbfbaf5b3b3a8f5bcb4ad">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: On September 15, 2021, FDA approved NDA
215310 for EXKIVITY (mobocertinib succinate) capsule, EQ 40 mg base,
for the treatment of adult patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-
approved test, whose disease has progressed on or after platinum-based
chemotherapy (EGFR exon 20 insertion-mutated NSCLC), under the Agency's
accelerated approval regulations, 21 CFR part 314, subpart H. The
accelerated approval of EXKIVITY (mobocertinib succinate) capsule, EQ
40 mg base, for EGFR exon 20 insertion-mutated NSCLC included a
required postmarketing trial intended to verify the clinical benefit of
EXKIVITY.
[[Page 57419]]
On October 19, 2023, FDA met with Takeda to discuss the voluntary
withdrawal of EXKIVITY (mobocertinib succinate) capsule, EQ 40 mg base,
according to Sec. 314.150(d) (21 CFR 314.150(d)). On October 25, 2023,
FDA recommended the applicant voluntarily request withdrawal of
approval of EXKIVITY (mobocertinib succinate) capsule, EQ 40 mg base,
for EGFR exon 20 insertion-mutated NSCLC according to Sec. 314.150(d)
because the postmarketing trial did not verify clinical benefit. FDA
also requested Takeda waive its opportunity for a hearing.
On March 15, 2024, Takeda submitted a letter asking FDA to withdraw
approval of NDA 215310 for EXKIVITY (mobocertinib succinate) capsule,
EQ 40 mg base, according to Sec. 314.150(d) and waiving its
opportunity for a hearing.
For the reasons discussed above, and in accordance with the
applicant's request, approval of NDA 215310 for EXKIVITY (mobocertinib
succinate) capsule, EQ 40 mg base, and all amendments and supplements
thereto, is withdrawn under Sec. 314.150(d). Distribution of EXKIVITY
(mobocertinib succinate) capsule, EQ 40 mg base, into interstate
commerce without an approved application is illegal and subject to
regulatory action (see sections 505(a) and 301(d) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)).
Dated: July 9, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-15371 Filed 7-12-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.